SYRE · Categories · Coverage
SYRE - Analyst coverage initiated
Spyre Therapeutics Inc. (SYRE) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for SYRE
- UBS initiated coverage on Spyre Therapeutics with a new price targetUBS initiated coverage of Spyre Therapeutics with a rating of Buy and set a new price target of $120.00
- Analyst initiated coverage on Spyre Therapeutics with a new price targetAnalyst initiated coverage of Spyre Therapeutics with a rating of Overweight and set a new price target of $110.00
- Raymond James initiated coverage on Spyre Therapeutics with a new price targetRaymond James initiated coverage of Spyre Therapeutics with a rating of Strong Buy and set a new price target of $80.00
- Mizuho initiated coverage on Spyre Therapeutics with a new price targetMizuho initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $53.00
- Citigroup initiated coverage on Spyre Therapeutics with a new price targetCitigroup initiated coverage of Spyre Therapeutics with a rating of Buy and set a new price target of $64.00
- Deutsche Bank initiated coverage on Spyre Therapeutics with a new price targetDeutsche Bank initiated coverage of Spyre Therapeutics with a rating of Buy and set a new price target of $43.00
- Leerink Partners initiated coverage on Spyre Therapeutics with a new price targetLeerink Partners initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $45.00
- Wolfe Research initiated coverage on Spyre Therapeutics with a new price targetWolfe Research initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $27.00
- Wedbush initiated coverage on Spyre Therapeutics with a new price targetWedbush initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $45.00
- Evercore ISI initiated coverage on Spyre TherapeuticsEvercore ISI initiated coverage of Spyre Therapeutics with a rating of Outperform
- Robert W. Baird initiated coverage on Spyre Therapeutics with a new price targetRobert W. Baird initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $50.00